Who is sponsoring NCT04457284?

NCT04457284 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT04457284 study?

NCT04457284 studies Colorectal Adenocarcinoma.

What drugs are being tested in NCT04457284?

Interventions: Temozolomide (TMZ), Cisplatin, Nivolumab.

What is the status of NCT04457284?

NCT04457284 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-03-11 · How we verify

A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer

NCT04457284 Phase 2 ACTIVE_NOT_RECRUITING

This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	18
Start date	2020-11-18
Completion	2026-07

Conditions

Colorectal Adenocarcinoma

Interventions

Temozolomide (TMZ)
Cisplatin
Nivolumab

Primary outcomes

Response — 1 year
will be evaluated in this study using the new international criteria proposed in RECIST 1.1 \[Eur J Ca 45:228-247, 2009\]. Changes in the largest diameter (unidimensional measurement) of the tumor and the shortest diameter of malignant lymph nodes are used with the RECIST criteria.

Countries

United States